What were the top-line results from Jazz Pharmaceuticals’ (NASDAQ:JAZZ) Phase 3 LAGOON trial?

The LAGOON trial evaluating Zepzelca (lurbinectedin) in second-line metastatic SCLC did not meet its primary endpoint. Median overall survival was 8.7 months for Zepzelca monotherapy and 10.9 months for Zepzelca plus irinotecan, both showing no statistically significant improvement versus control (10.7 months).

How was the LAGOON trial structured?

The multi-center, open-label study tested Zepzelca alone and combined with irinotecan, comparing both to investigator’s choice chemotherapy (topotecan or irinotecan) in relapsed, second-line metastatic SCLC patients.

Did Zepzelca show any survival advantage in the trial?

No. Neither the monotherapy nor combination arm achieved a statistically significant survival benefit compared to standard chemotherapy, failing the primary overall survival endpoint.

What was the safety profile observed in LAGOON?

Zepzelca maintained a consistent safety profile, with adverse events aligning with prior experience. No new or unexpected safety signals were reported in either monotherapy or combination arms.

How does the LAGOON result affect Zepzelca’s existing approvals?

The negative Phase 3 readout does not impact Zepzelca’s FDA approval in the U.S., which is based on the successful Phase 3 IMforte trial demonstrating improved survival with Zepzelca plus atezolizumab in first-line maintenance SCLC.

Image for illustrative purposes only. Not a real photo.

Jazz Pharmaceuticals Zepzelca misses survival endpoint in Phase 3 LAGOON lung cancer trial

Written by Heidi Cuthbert Published Jun 12, 2026, 12:08 PM

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced top-line results from the Phase 3 LAGOON clinical trial evaluating Zepzelca (lurbinectedin) in patients with relapsed, second-line metastatic small cell lung cancer (SCLC).

The confirmatory trial, which was conducted by Jazz’s development partner PharmaMar, did not achieve its primary endpoint of improving overall survival (OS).

The multi-center, open-label trial evaluated Zepzelca both as a monotherapy and in combination with the chemotherapy agent irinotecan, comparing both experimental arms against the investigator's choice of standard chemotherapy (topotecan or irinotecan).

The data revealed an overall median OS of 8.7 months for the Zepzelca monotherapy arm and 10.9 months for the Zepzelca-irinotecan combination arm.

Neither arm demonstrated a statistically significant survival advantage over the control group, which posted a median OS of 10.7 months.

Despite missing the primary efficacy threshold, the safety profile of Zepzelca remained consistent with previous clinical experience.

No new or unexpected safety signals were identified in either the monotherapy or combination cohorts, and the reported adverse events aligned with the established risk profiles of each individual therapeutic agent.

Jazz emphasized that the negative readout from the LAGOON study will have no structural impact on Zepzelca's existing commercial footprint or regulatory status in the United States.

The drug’s full FDA approval, which was secured in 2025, rests entirely on the successful Phase 3 IMforte trial.

That study demonstrated a statistically significant improvement in both overall survival and progression-free survival when using Zepzelca in combination with atezolizumab as a first-line maintenance treatment for extensive-stage SCLC.

Consequently, the company confirmed that the LAGOON results do not alter its previously issued 2026 financial guidance or its broader commercial strategy centered on first-line maintenance adoption.

Jazz Pharmaceuticals Zepzelca misses survival endpoint in Phase 3 LAGOON lung cancer trial

Frequently asked questions

Assets related to this article